01 · Process stage
PlannedSequence & pathway definition
Define the target molecular sequence, proposed synthetic route and the relevant structural parameters for the intended material.
Capabilities · Drug substance & biological inputs
Peptide & oligonucleotide processing
A proposed service scope for complex synthetic molecules, connecting sequence definition, solid-phase chemical synthesis, chromatographic purification and final material isolation.
PlannedCatalogue scope
Service statusPlanned
Planned.
Technical boundaries and readiness need confirmation before an activity could be presented as available.
Basis · Catalogue scope
- Status
- PlannedNo available service asserted
- Source-plan relationship
- Catalogue scopeProposed catalogue expansion
- Readiness
- Not establishedProduct and process evidence needed
- Facility roadmap
- First commercial batch target Q1 2028 · indicativeNot a service date
01 · Proposed service scope
Start with the product and its container.
Peptide and oligonucleotide processing is presented as a planned service domain. The exact molecular sequence, required purity profile and intended synthetic route would define its eventual scope.
The initial Boten plan details a protein raw-material module. The proposed services catalogue adds peptide and oligonucleotide synthesis as a proposed extension, which would require separate scope confirmation.
Chemical synthesis and biological expression are distinct technical subjects. Presentation in a shared catalogue category does not establish that biological infrastructure is appropriate for synthetic molecular workflows.
Catalogue boundary
A planned catalogue for scoped evaluation. Inclusion does not establish installed, qualified, licensed or available capability.
02 · Presentation families
Match the route to the format.
| Format | Planning note | Basis | Status |
|---|---|---|---|
| Synthetic peptides | Proposed synthetic peptide sequences, subject to feasibility and facility boundaries. | Catalogue scope | Planned |
| Oligonucleotides | Proposed nucleotide chains, requiring separate technical review and synthetic pathways. | Catalogue scope | Planned |
| Conjugated molecules | Proposed conjugated structures; conjugation complexity would inform any technical assessment. | Catalogue scope | Planned |
03 · Process scope for discussion
Make the sequence and its evidence visible.
02 · Process stage
PlannedMaterial & reagent specification
Determine the required starting materials, solvents, cleavage reagents and associated handling protocols.
03 · Process stage
PlannedSolid-phase synthesis
Consider the proposed chain elongation steps, coupling efficiency and relevant cleavage procedures.
04 · Process stage
PlannedPurification & chromatography
Define the required preparative chromatography steps and the target purity specifications for the isolated substance.
05 · Process stage
PlannedIsolation & concentration
Assess the intended lyophilisation or concentration methods for the final isolated synthetic material.
06 · Process stage
PlannedAnalytical characterisation
Connect the synthetic output to the relevant structural confirmation and analytical testing profiles.
Illustrative sequence
This is a technical discussion structure, not an operating procedure, approved process flow or representation of installed equipment.
04 · Supporting services
No service stands alone.
01PlannedInitial project scope
Protein raw-material production & purification
A separate planned module identified in the initial Boten project brief.
Explore proposed scope02PlannedCatalogue scope
Analytical method development
Product-specific test methods and analytical development questions.
Explore proposed scope03PlannedCatalogue scope
Small-molecule active ingredients
Proposed synthesis, isolation and purification domains; scope confirmation required.
Explore proposed scope05 · Readiness questions
A service claim needs a defined evidence base.
- Target molecule
- Exact molecular structure, sequence length and intended therapeutic application.
- Synthetic route
- Proposed chemical pathway, reaction conditions and necessary isolation techniques.
- Facility infrastructure
- Appropriate installed synthesis equipment and the corresponding environmental controls.
- Analytical methods
- Relevant chromatographic and structural characterisation methods for the intended molecule.
- Regulatory status
- Applicable site permissions for active pharmaceutical ingredient chemical synthesis.
- Technical agreement
- Clear definition of synthesis responsibilities and intellectual property boundaries.
06 · Practical questions
Before a technical discussion.
Is this service currently available?
No. The service is Planned. This page is a scope proposal and does not establish an operating peptide or oligonucleotide synthesis service.
Are synthetic molecules part of the initial project plan?
No. The initial plan describes a module for biological protein production. Peptide and oligonucleotide synthesis domains require separate technical review and scope confirmation.
What information helps define the question?
Identify the target sequence, proposed synthetic route, intended development stage and the specific technical question. Confidential data should only be shared through an agreed route.
Is there a service launch quarter?
No. No service-specific quarter is established. The project-wide indicative milestones do not commit any individual service to a start date.
Does a technical discussion establish supply?
No. Feasibility, scope, synthesis permissions, analytical evidence and any agreement would need to be established before a service commitment.
Professional enquiries
Discuss a defined question.
Describe the presentation, development question and destination relevant to the proposed scope. Do not infer service availability from this planning page.